CD38, a type II transmembrane glycoprotein, is widely recognized for its multifaceted roles in cellular processes, including calcium signaling, cell adhesion, and cyclic ADP-ribose synthesis. Historically, CD38 was first identified on the surface of thymocytes and later on a variety of cells, including B cells, T cells, and natural killer cells. This molecule functions primarily as an enzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+. The generated cADPR acts as a secondary messenger for calcium mobilization within cells, modulating various physiological processes. CD38 also has ADP-ribosyl cyclase and hydrolase activities, underlining its multifunctional enzymatic nature. Beyond its enzymatic roles, CD38 participates in cell-to-cell adhesion and signaling, especially in the context of immune responses.
CD38 Activators are chemical compounds devised to stimulate or augment the activity of CD38. By enhancing CD38's enzymatic functions, these activators influence its role in calcium signaling and NAD+ metabolism, thereby modulating related cellular events. Given the importance of calcium as a signaling molecule in various cellular processes, the controlled activation of CD38 might have profound impacts on cellular physiology, particularly in immune cells where CD38 is abundantly expressed. Activating CD38 could also impact NAD+ levels, given the enzyme's role in its metabolism. Understanding the mechanisms and effects of CD38 activators is crucial for gaining insights into the intricate balance of calcium signaling and NAD+ regulation in various cellular contexts. The exploration of CD38 activators can offer a deeper understanding of the protein's diverse functionalities and its impact on cellular homeostasis and communication.
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid can induce the differentiation of certain immune cells, potentially leading to upregulation of CD38. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
This glucocorticoid has immunosuppressive effects and may influence CD38 expression on certain immune cells. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $57.00 $200.00 | 15 | |
An agent that affects B cells and might influence CD38 expression on these cells. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
An immunosuppressive agent that may modulate CD38 expression by influencing T cell activation. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that might alter gene expression patterns, potentially influencing CD38 expression. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Known to modulate immune response, thalidomide may have an effect on CD38 expression on certain immune cells. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
A Bruton's tyrosine kinase inhibitor, ibrutinib affects B-cell signaling and may influence CD38 expression. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide might enhance CD38 expression on certain tumor cells, making them more susceptible to anti-CD38 therapies. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
A histone deacetylase inhibitor, panobinostat may upregulate CD38 expression on tumor cells. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $90.00 $251.00 | 5 | |
Used for bone metastases, it can influence immune cells and potentially modulate CD38 expression. |